Skip to main content

Table 2 Univariate and multivariate Cox regression analyses of liver-related mortality

From: “Sarcopenia and intramuscular fat deposition are associated with poor survival in Indonesian patients with hepatocellular carcinoma: a retrospective study”

Variable

No. at riska

No. of events

3-month survival, % ± SD

Univariate Cox regression analysis

Multivariate Cox regression analysis

HR

95% CI

P-value

HR

95% CI

P-value

Age

  < 55 years old

47

33

57 ± 7

1.000

(reference)

    

  ≥ 55 years old

53

44

45 ± 7

1.269

0.802–2.007

0.307

   

Gender

 Male§

74

60

46 ± 6

1.845

1.066–3.194

0.029

3.211

1.709–6.034

< 0.001

 Female

26

17

65 ± 9

1.000

(reference)

 

1.000

(reference)

 

Body mass index

 Underweight

31

24

48 ± 9

1.108

0.658–1.865

0.700

   

 Normal weight

44

35

50 ± 8

1.000

(reference)

    

 Overweight

25

18

55 ± 10

0.796

0.468–1.468

0.519

   

Sarcopenia

 No

69

49

62 ± 6

1.000

(reference)

 

1.000

(reference)

 

 Yesc

31

28

26 ± 8

2.950

1.836–4.740

<.0.001

1.921

1.129–3.268

0.016

IMF deposition

 No

35

17

89 ± 5

1.000

(reference)

 

1.000

(reference)

 

 Yesc

65

60

31 ± 6

5.487

3.106–9.693

<.0.001

3.580

1.895–6.764

< 0.001

Visceral adiposity

 No

71

55

48 ± 6

1.000

(reference)

    

 Yes

29

22

59 ± 6

0.890

0.542–1.461

0.644

   

Viral status

 HBV

58

51

40 ± 6

2.326

1.380–3.920

0.002

1.223

0.708–2.114

0.471

 HCV

8

6

50 ± 18

1.338

0.536–3.340

0.533

   

 None

34

20

71 ± 8

1.000

(reference)

 

1.000

(reference)

 

Child-Pugh class

 A

60

42

68 ± 6

1.000

(reference)

 

1.000

(reference)

 

 B

32

27

28 ± 8

2.129

1.306–3.469

0.002

0.406

0.087–1.901

0.252

 C

8

8

13 ± 12

5.069

2.342–10.973

<.0.001

0.578

0.110–3.031

0.516

TNM-AJCC stage AJCC - 8th Edition

 TNM-AJCC 1

20

13

85 ± 8

1.000

(reference)

 

1.000

(reference)

 

 TNM-AJCC 2

5

5

60 ± 22

3.586

1.244–10.339

0.018

1.304

0.439–3.875

0.633

 TNM-AJCC 3

32

21

56 ± 9

1.618

0.797–3.286

0.183

   

 TNM-AJCC 4

43

38

30 ± 7

3.663

1.908–7.031

<.0.001

1.177

0.341–4.063

0.796

TNM-LCSGJ stage

 TNM-LCSSGJ 2

21

14

86 ± 8

1.000

(reference)

 

1.000

(reference)

 

 TNM-LCSSGJ 3

32

22

53 ± 9

1.687

0.850–3.347

0.135

   

 TNM-LCSSGJ 4

47

41

34 ± 7

3.308

1.763–6.206

<.0.001

0.835

0.453–1.542

0.565

JIS score

 JIS score 1

18

12

89 ± 7

1.000

(reference)

 

1.000

(reference)

 

 JIS score 2

23

15

61 ± 10

1.426

0.737–4.494

0.362

   

 JIS score 3

31

23

54 ± 9

2.128

0.818–4.409

0.038

1.642

0.679–3.974

0.271

 JIS score 4c

23

22

17 ± 8

4.802

2.053–6.205

< 0.001

2.067

1.119–3.817

0.020

 JIS score 5

5

5

0 ± 0

28.373

8.802–91.456

<.0.001

3.843

0.938–15.735

0.061

BCLC stage

 A

7

2

100 ± 0

1.000

(reference)

 

1.000

(reference)

 

 B

25

13

88 ± 7

3.817

0.829–17.584

0.086

   

 C§

59

53

37 ± 6

12.419

2.907–53.067

0.001

2.396

1.248–4.600

0.009

 D§

9

9

0 ± 0

65.958

12.94–336.25

< 0.001

6.131

1.835–20.478

0.003

AFP level

  < 200 ng/ml

48

33

62 ± 7

1.000

(reference)

 

1.000

(reference)

 

  ≥ 200 ng/ml

52

44

40 ± 7

1.916

1.210–3.034

0.006

1.063

0.636–1.777

0.815

  1. HR Hazard ratio, CI Confidence interval, IMF Intramuscular fat, HCV Hepatitis C virus, HBV Hepatitis B virus, BCLC Barcelona Clinic Liver Cancer, TNM Tumour–node–metastasis, AJCC American Joint Committee of on Cancer, LCSGJ Liver Cancer Study Group of Japan, JIS Japan Integrated Staging; AFP Alpha-fetoprotein. aEqual to the total number of patients (N = 100). bNumber of deaths during the 3-month observation period. cVariables that independently predicted the HCC outcome based on univariate and multivariate analyses